Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

Jürgen Braun, Atulya (Atul) Deodhar, Ben Dijkmans, Piet Geusens, Joachim Sieper, Paul Williamson, Weichun Xu, Sudha Visvanathan, Daniel Baker, Neil Goldstein, Désirée Van Der Heijde

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Objective. To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods. Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (≥20% improvement in the ASsessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. Results. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2% versus 19.2%; P <0.001). By week 102, groups 1 and 2 were similar with regard to ASAS20 response (72.1% versus 73.9%); ASAS40 responses at week 102 were 45.9% versus 59.4%. No new safety issues were discerned. Conclusion. Infliximab demonstrated sustained efficacy and safety over 2 years in this large cohort of patients with active AS.

Original languageEnglish (US)
Pages (from-to)1270-1278
Number of pages9
JournalArthritis Care and Research
Volume59
Issue number9
DOIs
StatePublished - Sep 15 2008

Fingerprint

Ankylosing Spondylitis
Safety
Placebos
Infliximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Braun, J., Deodhar, A. A., Dijkmans, B., Geusens, P., Sieper, J., Williamson, P., ... Van Der Heijde, D. (2008). Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Care and Research, 59(9), 1270-1278. https://doi.org/10.1002/art.24001

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. / Braun, Jürgen; Deodhar, Atulya (Atul); Dijkmans, Ben; Geusens, Piet; Sieper, Joachim; Williamson, Paul; Xu, Weichun; Visvanathan, Sudha; Baker, Daniel; Goldstein, Neil; Van Der Heijde, Désirée.

In: Arthritis Care and Research, Vol. 59, No. 9, 15.09.2008, p. 1270-1278.

Research output: Contribution to journalArticle

Braun, J, Deodhar, AA, Dijkmans, B, Geusens, P, Sieper, J, Williamson, P, Xu, W, Visvanathan, S, Baker, D, Goldstein, N & Van Der Heijde, D 2008, 'Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period', Arthritis Care and Research, vol. 59, no. 9, pp. 1270-1278. https://doi.org/10.1002/art.24001
Braun, Jürgen ; Deodhar, Atulya (Atul) ; Dijkmans, Ben ; Geusens, Piet ; Sieper, Joachim ; Williamson, Paul ; Xu, Weichun ; Visvanathan, Sudha ; Baker, Daniel ; Goldstein, Neil ; Van Der Heijde, Désirée. / Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. In: Arthritis Care and Research. 2008 ; Vol. 59, No. 9. pp. 1270-1278.
@article{06d32651d8984a74b22c912e80b226f6,
title = "Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period",
abstract = "Objective. To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods. Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (≥20{\%} improvement in the ASsessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. Results. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2{\%} versus 19.2{\%}; P <0.001). By week 102, groups 1 and 2 were similar with regard to ASAS20 response (72.1{\%} versus 73.9{\%}); ASAS40 responses at week 102 were 45.9{\%} versus 59.4{\%}. No new safety issues were discerned. Conclusion. Infliximab demonstrated sustained efficacy and safety over 2 years in this large cohort of patients with active AS.",
author = "J{\"u}rgen Braun and Deodhar, {Atulya (Atul)} and Ben Dijkmans and Piet Geusens and Joachim Sieper and Paul Williamson and Weichun Xu and Sudha Visvanathan and Daniel Baker and Neil Goldstein and {Van Der Heijde}, D{\'e}sir{\'e}e",
year = "2008",
month = "9",
day = "15",
doi = "10.1002/art.24001",
language = "English (US)",
volume = "59",
pages = "1270--1278",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

AU - Braun, Jürgen

AU - Deodhar, Atulya (Atul)

AU - Dijkmans, Ben

AU - Geusens, Piet

AU - Sieper, Joachim

AU - Williamson, Paul

AU - Xu, Weichun

AU - Visvanathan, Sudha

AU - Baker, Daniel

AU - Goldstein, Neil

AU - Van Der Heijde, Désirée

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Objective. To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods. Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (≥20% improvement in the ASsessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. Results. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2% versus 19.2%; P <0.001). By week 102, groups 1 and 2 were similar with regard to ASAS20 response (72.1% versus 73.9%); ASAS40 responses at week 102 were 45.9% versus 59.4%. No new safety issues were discerned. Conclusion. Infliximab demonstrated sustained efficacy and safety over 2 years in this large cohort of patients with active AS.

AB - Objective. To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods. Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (≥20% improvement in the ASsessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. Results. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2% versus 19.2%; P <0.001). By week 102, groups 1 and 2 were similar with regard to ASAS20 response (72.1% versus 73.9%); ASAS40 responses at week 102 were 45.9% versus 59.4%. No new safety issues were discerned. Conclusion. Infliximab demonstrated sustained efficacy and safety over 2 years in this large cohort of patients with active AS.

UR - http://www.scopus.com/inward/record.url?scp=54949091496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949091496&partnerID=8YFLogxK

U2 - 10.1002/art.24001

DO - 10.1002/art.24001

M3 - Article

VL - 59

SP - 1270

EP - 1278

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -